Skip to main content
. 2022 Sep 19;163(11):bqac154. doi: 10.1210/endocr/bqac154

Figure 3.

Figure 3.

The AMPK-PGC-1α pathway is upregulated when LAMA4 is silenced. A, Relative Ppargc1a messenger RNA (mRNA) expression (PGC-1α) in adipocytes treated with control siRNA (n = 6) and Lama4 siRNA (n = 6). Reported as fold change with respect to paired control. * and ** indicate P less than or equal to .05 and .01, respectively. Data are means + SD. B, Relative Prkaa1 mRNA expression (AMPKα) in adipocytes treated with control small interfering (siRNA) (n = 6) and Lama4 siRNA (n = 6). C, Relative Tfam and Nrf1 mRNA expression in adipocytes treated with control siRNA (n = 6) and Lama4 siRNA (n = 6). D, Protein expression of AMPKα and p-AMPKα T172 in adipocytes treated with control siRNA (n = 4) and Lama4 siRNA (n = 4) was assessed by Western blot. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as the loading control for normalization. E, Relative Ucp1 mRNA expression in adipocytes treated with control siRNA (n = 4), Lama4 siRNA (n = 5), and Lama4 siRNA + 10 μM of compound C, an AMPK inhibitor (n = 4).